glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide
Description
And spoiler alert: Theyre really not into this trend
![glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-014-0142-7/MediaObjects/12933_2014_Article_142_Fig2_HTML.jpg)
New insights and promising therapies
![glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide](https://ars.els-cdn.com/content/image/1-s2.0-S1550413116302959-gr2.jpg)
Abbreviations: GIP, glucosedependent insulinotropic polypeptide
![glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide](http://www.jacc.org/cms/asset/6f80d2e8-a9a7-43e3-a38b-d6cbbb8bbb75/ga1.jpg)
Clinically significant drug-metabolizing enzyme- and transporter-mediated DDIs are yet to be reported
![glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide](https://www.frontiersin.org/files/Articles/1293926/xml-images/fcdhc-04-1293926-g001.webp)
and (4) article was an animal or in vitro study
![glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] Cardiovascular effects of Glucagon-like peptide](https://www.mdpi.com/ijms/ijms-24-10449/article_deploy/html/images/ijms-24-10449-g002.png)
And if insurance companies see significant cost increases because of the popularity of a new drug, that cost gets passed along in higher premiumswhich already grow at a frustrating rate year-after-year